Wockhardt Overview
- Year Founded
-
1967
- Status
-
Public
- Employees
-
4,084
- Stock Symbol
-
532300
- Investments
-
5
- Share Price
-
$21.59
- (As of Friday Closing)
Wockhardt General Information
Description
Wockhardt Ltd is a world-wide pharmaceutical and biotech company with presence in UK, Switzerland, Ireland, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland and Dubai. The company's only reportable business segment is Pharmaceutical business. It has presence in India, USA, Europe, Rest of the world. The company generates majority of revenue from Europe.
Contact Information
Website
www.wockhardt.comCorporate Office
- Wockhardt Towers
- Bandra-Kurla Complex, Bandra (East)
- Mumbai, 400051
- India
Corporate Office
- Wockhardt Towers
- Bandra-Kurla Complex, Bandra (East)
- Mumbai, 400051
- India
Wockhardt Timeline
Wockhardt Stock Performance
As of 13-Nov-2026, Wockhardt’s stock price is $21.59. Its current market cap is $3.51B with 163M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $21.59 | $21.95 | $11.60 - $25.47 | $3.51B | 163M | 78.2K | $0.27 |
Wockhardt Financials Summary
As of 30-Sep-2026, Wockhardt has a trailing 12-month revenue of $405M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 3,781,339 | 2,206,782 | 2,979,960 | 1,369,597 |
| Revenue | 404,556 | 375,380 | 344,737 | 336,893 |
| EBITDA | 96,097 | 75,370 | 52,391 | 10,630 |
| Net Income | 44,220 | 24,105 | (5,558) | (55,927) |
| Total Assets | 926,797 | 913,064 | 951,025 | 917,218 |
| Total Debt | 233,001 | 236,665 | 236,266 | 282,516 |
Wockhardt Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Wockhardt Comparisons
Industry
Financing
Details
Wockhardt Competitors (61)
One of Wockhardt’s 61 competitors is Strides Pharma Science, a Formerly VC-backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Strides Pharma Science | Formerly VC-backed | Bangalore, India | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel |
Wockhardt Patents
Wockhardt Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026146530-A1 | Atorvastatin oral suspension with improved stability and a method for the production thereof | Pending | 30-Dec-2024 | ||
| WO-2026133354-A1 | A stable oral pharmaceutical composition of ferrous fumarate | Pending | 19-Dec-2024 | ||
| WO-2026013693-A1 | A stable prolonged release tablets of sodium valproate and valproic acid | Pending | 08-Jul-2024 | ||
| AU-2025246337-A1 | A stable oral liquid pharmaceutical formulation of clonidine | Pending | 29-Mar-2024 | ||
| WO-2025203052-A1 | A stable oral liquid pharmaceutical formulation of clonidine | Pending | 29-Mar-2024 | A61K9/0095 |
Wockhardt Signals
Wockhardt Acquisitions (5)
Wockhardt’s most recent deal was a Merger/Acquisition with Laboratoires Negma for . The deal was made on 10-Nov-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Laboratoires Negma | 10-Nov-2007 | Merger/Acquisition | Pharmaceuticals | ||
| Morton Grove Pharmaceuticals | 23-Oct-2007 | Merger/Acquisition | Drug Delivery | ||
| Pinewood Healthcare | 03-Oct-2006 | Merger/Acquisition | Pharmaceuticals | ||
| Esparma | 06-May-2004 | Merger/Acquisition | Pharmaceuticals | ||
| CP Pharmaceuticals | 15-Jul-2003 | Merger/Acquisition | Pharmaceuticals |
Wockhardt ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.52 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Wockhardt Exits (2)
Wockhardt’s most recent exit was on 23-Oct-2007 from Morton Grove Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Morton Grove Pharmaceuticals | 23-Oct-2007 | Completed |
|
||
| Esparma | 06-May-2004 | Merger/Acquisition | Completed |
Wockhardt Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Pinewood Healthcare | Clonmel, Ireland | 1976 |
Wockhardt FAQs
-
When was Wockhardt founded?
Wockhardt was founded in 1967.
-
Where is Wockhardt headquartered?
Wockhardt is headquartered in Mumbai, India.
-
What is the size of Wockhardt?
Wockhardt has 4,084 total employees.
-
What industry is Wockhardt in?
Wockhardt’s primary industry is Pharmaceuticals.
-
Is Wockhardt a private or public company?
Wockhardt is a Public company.
-
What is Wockhardt’s stock symbol?
The ticker symbol for Wockhardt is 532300.
-
What is the current stock price of Wockhardt?
As of 13-Nov-2026 the stock price of Wockhardt is $21.59.
-
What is the current market cap of Wockhardt?
The current market capitalization of Wockhardt is $3.51B.
-
What is Wockhardt’s current revenue?
The trailing twelve month revenue for Wockhardt is $405M.
-
Who are Wockhardt’s competitors?
Strides Pharma Science, Evonile Pharma, Aurobindo Pharma, GSK, and Teva Pharmaceutical Industries are some of the 61 competitors of Wockhardt.
-
What is Wockhardt’s annual earnings per share (EPS)?
Wockhardt’s EPS for 12 months was $0.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process